Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overview of the therapeutic strategies for ER positive breast cancer.

Biochemical pharmacology - 1 Jun 2023

Blakely Brianna, Shin Seobum, Jin Kideok

Abstract excerpt

Estrogen Receptor is the driving transcription factor in about 75% of all breast cancers, which is the target of endocrine therapies, but drug resistance is a common clinical problem. ESR1 point mutations at the ligand binding domain are frequently identified in metastatic tumor and ctDNA (Circulating tumor DNA) derived from ER positive breast cancer patients with endocrine therapies. Although endocrine therapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Drug Resistance, Neoplasm
Share to Estrogen Receptor alpha

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Point Mutation

Share to Receptors, Estrogen

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 37068524
DOI: 10.1016/j.bcp.2023.115552
PMCID: PMC10394654

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overview of the therapeutic strategies for ER positive breast cancer.PMID 37068524Read ↗

Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic ApproachesSemantic proximity Read ↗

Targeted therapies for ER+/HER2- metastatic breast cancerSemantic proximity Read ↗

ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.Semantic proximity Read ↗

Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy ResistanceSemantic proximity Read ↗

Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer.Semantic proximity Read ↗

Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance.Semantic proximity Read ↗

Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2- Breast CancerSemantic proximity Read ↗

Molecular Changes During Breast Cancer and Mechanisms of Endocrine Therapy Resistance.Semantic proximity Read ↗

Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goalsSemantic proximity Read ↗

Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer.Semantic proximity Read ↗

Estrogen receptor mutations and their role in breast cancer progression.Semantic proximity Read ↗

How I treat endocrine-dependent metastatic breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.